Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer

Abstract

This study demonstrates excellent tolerability, with only occasional complications. Most of these occurred during the year following implantation. A TIVAP may also be left in place for an extremely long time.

Ultrasound‐guided totally implantable venous access device through the right innominate vein in older patients is safe and reliable

“…24 The late complications rate from long-term use was 5.45% (3/55), which was consistent with the reported literature. 12,25 Two patients had catheter-related infections on the 127th and 369th days after operation. The blood culture showed Staphylococcus aureus.…”

“…At present, ultrasound (US)‐guided percutaneous puncture of the internal jugular vein (IJV) and subclavian vein (SCV) are the two main approaches for TIVAD . Complications include hemothorax, pneumothorax, catheter displacement and catheter rupture, which delay the treatment of the disease and reduce the effective utilization rate of the transfusion port …”

“…3,4 Complications include hemothorax, pneumothorax, catheter displacement and catheter rupture, which delay the treatment of the disease and reduce the effective utilization rate of the transfusion port. 5 Recently, US-guided innominate vein (INV) access central venous catheterization is reported to be an appropriate option of high puncture success rate and low puncture complications, and this technique has some advantages over IJV approaches. 6,7 Furthermore, puncture of the INV for TIVAD is rarely reported.…”

Utility of totally implantable venous access ports in patients with breast cancer

“…In addition, some drugs are toxic to the veins particularly peripheral veins . So the implantation of a TIVAP is required as its advantage of easy access of central veins . It was reported that there were significant less complications in TIVAPs than what in other accesses for chemotherapy and it could be used in entire treatment cycle safely .…”

“…2 So the implantation of a TIVAP is required as its advantage of easy access of central veins. 3 It was reported that there were significant less complications in TIVAPs than what in other accesses for chemotherapy and it could be used in entire treatment cycle safely. 4 Generally, in TIVAPs implantation, we use the basilic vein, subclavian vein, external jugular vein, or the internal jugular vein (IJV) as puncture sites.…”